Source: Thailand Medical News Dec 15, 2019 4 years, 11 months, 6 days, 3 hours, 34 minutes ago
Scientists from QIMR Berghofer Medical Research Institute, Brisbane have discovered a potential new
cancer immunotherapy target that involves switching off a regulatory cell to stop tumors growing and spreading.
.jpg)
The new study findings have been published today in
Cancer Discovery, a journal of the American Association for
Cancer Research.
Associate Professor Dr Michele Teng, senior researcher and head of QIMR Berghofer's Cancer Immunoregulation and
Immunotherapy Laboratory, said in future the discovery could potentially help treat patients with
cancers where other current
immunotherapies have not worked.
Dr Teng told
Thailand Medical News, "Our work on mice shows for the first time that many tumors display the molecule MR1 on their cell surface, and when it's present, this molecule turns on an important regulatory cell that prevents the body's own immune system from fighting the
cancer. We found if a type of regulatory cell called MAIT (mucosal-associated invariant T) cells are turned on, they stop immune or white blood cells known as T and NK cells from attacking and killing off tumor cells.”
She added, "The
cancer is effectively creating its own defense mechanism to evade immune attack and survive. The display of MR1 activates the MAIT cells, which in turn switch off
cancer-fighting T and NK cells. While other regulatory cells of the immune system are known to stop T and NK cells from killing tumor cells, this is the first time it's been shown that these regulatory MAIT cells can do this job."
Dr Teng said her team found that by giving mice an antibody that blocked MR1, this stopped the MAIT cells from becoming activated, and the T and NK cells could respond, slowing
cancer growth and stopping it spreading.
This work demonstrates that antibodies that block MR1 could in future be an effective new
immunotherapy.
Dr Teng added, "It probably won't work on every
cancer, but it looks like it could be effective in treating
cancers that can display the MR1 molecule. It also means this display of MR1 could be used to screen which patients would respond to this
immunotherapy. We now need to replicate this research in humans."
Dr Teng said while the research was at a very early stage and required more work, it was promising.
She said, "The next step is to try to understand what kind of human tumors display MR1 as a protective mechanism, which would then help us identify which tumors would respond best to MR1-blocking
immunotherapy."
Although
immunotherapies have been effectively used to treat more than 15 diffe
rent
cancer types but the proportion of patients that respond for each
cancer can differ. In patients with advanced melanoma for example, current approved
immunotherapies work in about 50 percent of cases, but half do not respond, and that's why it is of dire need to find new therapies.
Reference : Juming Yan et al. MAIT cells promote tumor initiation, growth and metastases via tumor MR1, Cancer Discovery (2019). DOI: 10.1158/2159-8290.CD-19-0569
